Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SMO | Q99835 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 2/20 | 0.50 |
| ▸ | UBE2T | Q9NPD8 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13036340 | 0.87 | PPARG (0.54) | OPRM1OPRK1HRH3KDM4EGAA | |
| SCHEMBL7527367 | 0.86 | KDM4E (0.52) | OPRM1OPRK1HRH3KDM4EGAA | |
| Potassium Ion SCHEMBL7532631 | 0.84 | KDM4E (0.54) | OPRM1OPRK1HRH3KDM4EGAA | |
| SCHEMBL7525198 | 0.84 | KDM4E (0.54) | OPRM1OPRK1HRH3KDM4EGAA | |
| SCHEMBL30753988 | 0.84 | HRH3 (0.70) | OPRM1OPRK1HRH3GAASMO | |
| SCHEMBL4460927 | 0.84 | RAB9A (0.56) | OPRM1OPRK1HRH3KDM4ESMO | |
| SCHEMBL7528163 | 0.83 | KMT2A (0.68) | HRH3KDM4EGAANPC1RAB9A | |
| SCHEMBL30754039 | 0.83 | HRH3 (0.56) | OPRM1OPRK1HRH3SMOPARP1 | |
| Hydrochloric Acid SCHEMBL5009801 | 0.82 | RAB9A (0.55) | OPRM1OPRK1HRH3KDM4ESMO | |
| SCHEMBL31747424 | 0.82 | OPRM1 (0.57) | OPRM1OPRK1HRH3SMOPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1824829-B1 | 3-SUBSTITUTED PYRIDINE DERIVATIVES AS H3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-05-05 | — | — | EP | claimed |
| EP-1824829-A1 | 3-SUBSTITUTED PYRIDINE DERIVATIVES AS H3 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2007-08-29 | — | — | EP | claimed |
| US-20060122187-A1 | Pyridine derivatives as H3 antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-08 | — | — | US | claimed |
| WO-2006058649-A1 | 3-SUBSTITUTED PYRIDINE DERIVATIVES AS H3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-08 | — | — | WO | claimed |
| EP-1824829-B1 | 3-SUBSTITUTED PYRIDINE DERIVATIVES AS H3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-05-05 | — | — | EP | disclosed |
| WO-2009141386-A1 | DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-11-26 | — | — | WO | disclosed |
| US-7528135-B2 | Pyridine derivatives as H3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1824829-A1 | 3-SUBSTITUTED PYRIDINE DERIVATIVES AS H3 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2007-08-29 | — | — | EP | disclosed |
| US-20060122187-A1 | Pyridine derivatives as H3 antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-08 | — | — | US | disclosed |
| WO-2006058649-A1 | 3-SUBSTITUTED PYRIDINE DERIVATIVES AS H3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-08 | — | — | WO | disclosed |
| EP-0882716-B1 | PYRIDINECARBOXAMIDE DERIVATIVES | NISSHIN PHARMA INC (JP) | 2002-04-10 | — | — | EP | disclosed |
| US-6046201-A | Pyridinecarboxamide derivatives | NISSHIN FLOUR MILLING CO., LTD. (JP) | 2000-04-04 | — | — | US | disclosed |
| EP-0882716-A1 | PYRIDINECARBOXAMIDE DERIVATIVES | Nisshin Flour Milling Co., Ltd. (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122187-A1 | Pyridine derivatives as H3 antagonists | HRH3, HRH4, HRH2 | OPRM1 165/4885OPRK1 91/4885HRH3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.